Spectrum Pharmaceuticals Announces Completion Of Patient Accrual In Its EOquin(R) Pilot Study, Prior To Initiating Phase 3 Studies In The U.S.

... Spectrum Pharmaceuticals (Nasdaq: SPPI) announced today that the Company has completed patient accrual in the U.S. pilot safety study of EOquin(R) in patients with noninvasive bladder cancer. In this study, EOquin(R) was found to be well tolerated when administered to patients immediately following surgery for noninvasive bladder cancer in clinical results to date. [click link for full article] ...